These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18245139)

  • 61. A cobalamin metabolic defect with homocystinuria, methylmalonic aciduria and macrocytic anemia.
    Mamlok RJ; Isenberg JN; Rassin DK; Norcross K; Tallan HH
    Neuropediatrics; 1986 May; 17(2):94-9. PubMed ID: 2873525
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gene discovery in methylmalonic aciduria and homocystinuria.
    Thiele J; Van Raamsdonk JM
    Clin Genet; 2006 May; 69(5):402-3. PubMed ID: 16650077
    [No Abstract]   [Full Text] [Related]  

  • 63. Phenotype, treatment practice and outcome in the cobalamin-dependent remethylation disorders and MTHFR deficiency: Data from the E-HOD registry.
    Huemer M; Diodato D; Martinelli D; Olivieri G; Blom H; Gleich F; Kölker S; Kožich V; Morris AA; Seifert B; Froese DS; Baumgartner MR; Dionisi-Vici C; ; Martin CA; Baethmann M; Ballhausen D; Blasco-Alonso J; Boy N; Bueno M; Burgos Peláez R; Cerone R; Chabrol B; Chapman KA; Couce ML; Crushell E; Dalmau Serra J; Diogo L; Ficicioglu C; García Jimenez MC; García Silva MT; Gaspar AM; Gautschi M; González-Lamuño D; Gouveia S; Grünewald S; Hendriksz C; Janssen MCH; Jesina P; Koch J; Konstantopoulou V; Lavigne C; Lund AM; Martins EG; Meavilla Olivas S; Mention K; Mochel F; Mundy H; Murphy E; Paquay S; Pedrón-Giner C; Ruiz Gómez MA; Santra S; Schiff M; Schwartz IV; Scholl-Bürgi S; Servais A; Skouma A; Tran C; Vives Piñera I; Walter J; Weisfeld-Adams J
    J Inherit Metab Dis; 2019 Mar; 42(2):333-352. PubMed ID: 30773687
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Psychosis, paraplegia and coma revealing methylenetetrahydrofolate reductase deficiency in a 56-year-old woman.
    Michot JM; Sedel F; Giraudier S; Smiejan JM; Papo T
    J Neurol Neurosurg Psychiatry; 2008 Aug; 79(8):963-4. PubMed ID: 18356252
    [No Abstract]   [Full Text] [Related]  

  • 65. Late-onset combined homocystinuria and methylmalonic aciduria (cblC) and neuropsychiatric disturbance.
    Tsai AC; Morel CF; Scharer G; Yang M; Lerner-Ellis JP; Rosenblatt DS; Thomas JA
    Am J Med Genet A; 2007 Oct; 143A(20):2430-4. PubMed ID: 17853453
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Early onset methylmalonic aciduria and homocystinuria cblC type with demyelinating neuropathy.
    Frattini D; Fusco C; Ucchino V; Tavazzi B; Della Giustina E
    Pediatr Neurol; 2010 Aug; 43(2):135-8. PubMed ID: 20610126
    [TBL] [Abstract][Full Text] [Related]  

  • 67. EEG in assessing hydroxycobalamin therapy in neonatal methylmalonic aciduria with homocystinuria.
    Bellieni CV; Ferrari F; De Felice C; Bagnoli F; Cioni M; Farnetani M; Gatti MG; Buonocore G
    Biol Neonate; 2000 Nov; 78(4):327-30. PubMed ID: 11093015
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Milder clinical and biochemical phenotypes associated with the c.482G>A (p.Arg161Gln) pathogenic variant in cobalamin C disease: Implications for management and screening.
    Almannai M; Marom R; Divin K; Scaglia F; Sutton VR; Craigen WJ; Lee B; Burrage LC; Graham BH
    Mol Genet Metab; 2017 Sep; 122(1-2):60-66. PubMed ID: 28693988
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Generation of a Human iPSC line (SDQLCHi021-A) from a patient with methylmalonic acidemia cblC type carrying compound heterozygous mutations in MMAHC gene.
    Guan J; Li Z; Zhang H; Yang X; Ma Y; Li Y; Dong R; Gai Z; Liu Y
    Stem Cell Res; 2020 Mar; 43():101709. PubMed ID: 32058304
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ocular manifestations of cobalamin C type methylmalonic aciduria with homocystinuria.
    Fuchs LR; Robert M; Ingster-Moati I; Couette L; Dufier JL; de Lonlay P; Brodie SE
    J AAPOS; 2012 Aug; 16(4):370-5. PubMed ID: 22929452
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Genetic and cellular studies of oxidative stress in methylmalonic aciduria (MMA) cobalamin deficiency type C (cblC) with homocystinuria (MMACHC).
    Richard E; Jorge-Finnigan A; Garcia-Villoria J; Merinero B; Desviat LR; Gort L; Briones P; Leal F; Pérez-Cerdá C; Ribes A; Ugarte M; Pérez B;
    Hum Mutat; 2009 Nov; 30(11):1558-66. PubMed ID: 19760748
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical neurogenetics: neurologic presentations of metabolic disorders.
    Kwon JM; D'Aco KE
    Neurol Clin; 2013 Nov; 31(4):1031-50. PubMed ID: 24176422
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An X-linked cobalamin disorder caused by mutations in transcriptional coregulator HCFC1.
    Yu HC; Sloan JL; Scharer G; Brebner A; Quintana AM; Achilly NP; Manoli I; Coughlin CR; Geiger EA; Schneck U; Watkins D; Suormala T; Van Hove JL; Fowler B; Baumgartner MR; Rosenblatt DS; Venditti CP; Shaikh TH
    Am J Hum Genet; 2013 Sep; 93(3):506-14. PubMed ID: 24011988
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Late-onset cobalamin-C disorder: a challenging diagnosis.
    Ben-Omran TI; Wong H; Blaser S; Feigenbaum A
    Am J Med Genet A; 2007 May; 143A(9):979-84. PubMed ID: 17431913
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epimutation of MMACHC compound to a genetic mutation in cblC cases.
    Zhang X; Chen Q; Song Y; Guo P; Wang Y; Luo S; Zhang Y; Zhou C; Li D; Chen Y; Wei H
    Mol Genet Genomic Med; 2021 Jun; 9(6):e1625. PubMed ID: 33982424
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Early-onset combined methylmalonic aciduria and homocystinuria: neuroradiologic findings.
    Rossi A; Cerone R; Biancheri R; Gatti R; Schiaffino MC; Fonda C; Zammarchi E; Tortori-Donati P
    AJNR Am J Neuroradiol; 2001 Mar; 22(3):554-63. PubMed ID: 11237984
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Maculopathy and retinal degeneration in cobalamin C methylmalonic aciduria and homocystinuria.
    Tsina EK; Marsden DL; Hansen RM; Fulton AB
    Arch Ophthalmol; 2005 Aug; 123(8):1143-6. PubMed ID: 16087854
    [No Abstract]   [Full Text] [Related]  

  • 78. Late-onset cobalamin C disease: rare but treatable.
    Aliyar A; Endrakanti M; Singh RK; Elavarasi A; Gupta N; Vibha D; Tripathi M
    Pract Neurol; 2022 Jul; ():. PubMed ID: 35803728
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical and biochemical outcome after hydroxocobalamin dose escalation in a series of patients with cobalamin C deficiency.
    Matos IV; Castejón E; Meavilla S; O'Callaghan M; Garcia-Villoria J; López-Sala A; Ribes A; Artuch R; Garcia-Cazorla A
    Mol Genet Metab; 2013 Aug; 109(4):360-5. PubMed ID: 23746552
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical and biochemical outcomes in cobalamin C deficiency with use of high-dose hydroxocobalamin in the early neonatal period.
    Kacpura A; Frigeni M; Gunther K; Farach L
    Am J Med Genet A; 2022 Jun; 188(6):1831-1835. PubMed ID: 35156754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.